The frequency of associated comorbidity and the cost of treatments in patients with atopic dermatitis (AD) followed up in primary care settings are poorly known. We carried out a retrospective cohort study on a longitudinal electronic medical records database of patients consulting a panel of general practitioners in France. All subjects with AD diagnosed during the first year of life were selected and matched with infants without the disease according to sex (1,163 vs. 1,163). Subjects were followed up for 9 years. Associated diseases, drug consumptions and available medical costs were detailed. Comparisons between subjects and controls were carried out. Subjects with AD had more comorbidities than others, especially in respiratory and ophthalmic system organs. The number of prescribed treatments in the field of skin diseases as well as overall medical costs (general practitioner consultations and prescribed drugs) were higher among atopic subjects, but differences were attenuated with age.

Keywords:
Follow-up, Children, Atopic dermatitis, General practitioners
1.
Misery L: Atopic dermatitis: new trends and perspectives. Clin Rev Allergy Immunol 2011;41:296-297.
2.
Williams HC: Clinical practice. Atopic dermatitis. N Engl J Med 2005;352:2314-2324.
3.
DaVeiga SP: Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc 2012;33:227-234.
4.
Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC: The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005;22:192-199.
5.
Misery L, Finlay AY, Martin N, Boussetta S, Nguyen C, Myon E, Taieb C: Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology 2007;215:123-129.
6.
Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy AM, Nguyen JM, Leux C, Misery L, Young P, Chastaing M, Danou N, Lombrail P, Boralevi F, Lacour JP, Mazereeuw-Hautier J, Stalder JF, Barbarot S: Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011;165:808-814.
7.
Misery L: Therapeutic perspectives in atopic dermatitis. Clin Rev Allergy Immunol 2011;41:267-271.
8.
Mancini AJ, Kaulback K, Chamlin SL: The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol 2008;25:1-6.
9.
Williams HC, Strachan DP: The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol 1998;139:834-839.
10.
Willis-Owen SA, Morar N, Willis-Owen CA: Atopic dermatitis: insights from linkage overlap and disease co-morbidity. Expert Rev Mol Med 2007;9:1-13.
11.
Luoma R, Koivikko A, Viander M: Development of asthma, allergic rhinitis and atopic dermatitis by the age of five years. A prospective study of 543 newborns. Allergy 1983;38:339-346.
12.
Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH: Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441-446.
13.
Rogers AJ, Celedón JC, Lasky-Su JA, Weiss ST, Raby BA: Filaggrin mutations confer susceptibility to atopic dermatitis but not to asthma. J Allergy Clin Immunol 2007;120:1332-1337.
14.
Roguedas AM, Audrezet MP, Scotet V, Dupré-Goetghebeur D, Ferec C, Misery L: Intrinsic atopic dermatitis is associated with a beta-2 adrenergic receptor polymorphism. Acta Derm Venereol 2006;86:447-448.
15.
Weidinger S, Illig T, Baurecht H, Irvine AD, Rodriguez E, Diaz-Lacava A, Klopp N, Wagenpfeil S, Zhao Y, Liao H, Lee SP, Palmer CN, Jenneck C, Maintz L, Hagemann T, Behrendt H, Ring J, Nothen MM, McLean WH, Novak N: Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006;118:214-219.
16.
Misery L, Boussetta S, Shooneman P, Taieb C: Dermatological future of European patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2009;23:1383-1388.
17.
Williams HC, Grindlay DJ: What's new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 1. Definitions, causes and consequences of eczema. Clin Exp Dermatol 2010;35:12-17.
18.
Burr ML, Dunstan FD, Hand S, Ingram JR, Jones KP: The natural history of eczema from birth to adult life: a cohort study. Br J Dermatol 2013;168:1339-1342.
19.
Spergel JM, Paller AS: Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112(suppl 6):S118-S127.
20.
Wood RA, Doran TF: Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Curr Opin Pediatr 1995;7:615-627.
21.
Guglielmetti S, Dart JK, Calder V: Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol 2010;10:478-485.
22.
Schnopp C, Ring J, Mempel M: The role of antibacterial therapy in atopic eczema. Expert Opin Pharmacother 2010;11:929-936.
23.
Schuttelaar ML, Vermeulen KM, Coenraads PJ: Costs and cost-effectiveness analysis of treatment in children with eczema by nurse practitioner vs. dermatologist: results of a randomized, controlled trial and a review of international costs. Br J Dermatol 2011;165:600-611.
24.
Stalder JF, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari S, Oranje A, Deleuran M, Cambazard F, Svensson A, Simon D, Benfeldt E, Reunala T, Mazereeuv J, Boralevi F, Kunz B, Misery L, Mortz CG, Darsow U, Gelmetti C, Diepgen T, Ring J, Moehrenschlager M, Gieler U, Taïeb A; PO-SCORAD Investigators Group: Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy 2011;66:1114-1121.
25.
Misery L, Ortonne JP, Cambazard F, Guillet G, Thomas L, Lorette G, Durosier V, Rahhali N, Auges M, Taieb C: PPAD: a tool for presumption of atopic dermatitis. J Dermatol 2012;39:151-155.
26.
Ehlken B, Möhrenschlager M, Kugland B, Berger K, Quednau K, Ring J: Cost-of-illness study in patients suffering from atopic eczema in Germany (in German). Hautarzt 2005;56:1144-1151.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.